Old Warnings.
New Conversation.
On February 12, 2026, the FDA approved labeling changes for six menopausal hormone therapy products, removing cardiovascular disease, breast cancer and probable dementia statements from their boxed warnings. Other warnings and risks remain; this does not mean all hormone products are FDA-approved or risk-free.
Source: FDA announcement, February 12, 2026
Early results from the 2002 Women's Health Initiative influenced how hormone therapy was discussed and prescribed. Later analyses showed that age, time since menopause, and the specific therapy matter when weighing benefits and risks.
The labeling changes concern six products, not every hormone product. They are a reason to revisit your questions with a qualified healthcare provider, not a promise of safety or suitability for you.
This page is educational commentary based on publicly reported updates to the FDA's menopause hormone therapy labeling. It is not medical advice. Individual decisions about hormone therapy should be made with a qualified clinician who knows your history.
What the update means
- Six products received specific boxed-warning changes on February 12, 2026.
- Other warnings and risks remain. Hormone therapy is not a one-size-fits-all decision.
- The changes do not mean all hormone products are FDA-approved or risk-free.
Why this matters for you
You can ask informed questions about your options. Your personal health history and the specific product matter when discussing benefits and risks.